This is an observational longitudinal study which will collect routine demographic, laboratory and clinical parameters of patients with chronic kidney disease (CKD) in the Silesian and Warmia and Mazury Regions (Poland) aimed at predicting incident cardiovascular disease and cardiovascular and renal events using machine learning and artificial intelligence approaches. There will be a subgroup analysis of patients with diabetes and CKD.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* CKD defined as estimated glomerular filtration rate (eGFR) \< 60ml/min/1.73 m2 and/or urine albumin creatinine ratio ( UACR) \> 30 mg/g lasting at least 3 months
* CKD regardless of eGFR/albuminuria when documented otherwise (by means of imaging, renal biopsy result, genetic background, etc)
Exclusion Criteria:
* Death during hospital stay
* Terminal stage of cancer
* Lack of an informed consent
Primary outcome measure(s)
Incident Coronary Artery Disease — Annually, 10 years from enrollment New occurrence of coronary artery disease as diagnosed by standard medical procedures.
Myocardial Infarction — Annually, 10 years from enrollment New occurrence of myocardial infarction as confirmed by electrocardiogram and/or biomarkers.
New onset heart failure or exacerbation of heart failure — Annually, 10 years from enrollment New-Onset Heart Failure: Diagnosis based on the ESC guidelines, which include symptoms such as breathlessness, ankle swelling, and fatigue; objective evidence of cardiac dysfunction or structural abnormality in echocardiography; and response to treatment directed towards heart failure.
Hospitalization for decompensated heart failure: Requires unscheduled admission to a healthcare facility with heart failure as the primary reason for admission.
Stroke or Transient Ischemic Attack — Annually, 10 years from enrollment New occurrence of stroke as confirmed by neuroimaging or transient ischemic attack ascertained by typical symptoms.
Peripheral Vascular Disease Peripheral Vascular Disease Peripheral Vascular Disease Peripheral Vascular Disease Peripheral Vascular Disease — Annually, 10 years from enrollment New diagnosis of peripheral vascular disease confirmed by imaging studies.
Atrial Fibrillation — Annually, 10 years from enrollment Incident atrial fibrillation confirmed by electrocardiogram.
Death Due to Cardiovascular Cause — Annually, 10 years from enrollment Death where the primary cause is attributed to cardiovascular disease.
Progression of Chronic Kidney Disease — Annually, 10 years from enrollment Progression to macroalbuminuria or doubling of serum creatinine with a decrease of eGFR to less than 45 ml/min/1.73m\^2 compared to baseline.
End-Stage Renal Disease or Renal Death — Annually, 10 years from enrollment Onset of end-stage renal disease requiring initiation of maintenance dialysis or kidney transplantation, or death due to renal causes.
Trial sites (2)
Facility
City
Region
Status
Wojewódzki Szpital Specjalistyczny w Olsztynie
Olsztyn
Poland
Recruiting
Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Stanisława Szyszko Śląskiego Uniwersytetu Medycznego w Katowicach
Zabrze
Poland
Recruiting
More Medical University of Silesia trials in Poland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
